Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + cyclophosphamide + epirubicin + etoposide + lomustine + methotrexate
- Development stage
- Preclinical
- Lead developer
- Michigan State University
- Modality
- Small Molecules
- Administration
- Intravenous, Oral, Intrathecal
01
Overview
A multi-agent chemotherapy combination consisting of cisplatin, cyclophosphamide, epirubicin, etoposide, lomustine, and methotrexate. This combination includes alkylating agents (cyclophosphamide, lomustine), platinum compounds (cisplatin), anthracyclines (epirubicin), topoisomerase inhibitors (etoposide), and antimetabolites (methotrexate), potentially providing broad-spectrum cytotoxic activity against cancer cells through multiple mechanisms.
- Other names
- CCNU + cisplatin + cyclophosphamide + epirubicin + etoposide + methotrexate
02
Targets
DNADHFR (Dihydrofolate reductase)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on cisplatin + cyclophosphamide + epirubicin + etoposide + lomustine + methotrexate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + cyclophosphamide + epirubicin + etoposide + lomustine + methotrexate.